US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

8.42

+0.29003.57%

Post-market: 8.450.0320+0.38%19:30 EDT

Volume:663.61K

Turnover:5.56M

Market Cap:520.72M

PE:-2.92

High:8.58

Open:8.24

Low:8.19

Close:8.13

52wk High:13.67

52wk Low:3.50

Shares:61.84M

Float Shares:39.72M

Volume Ratio:0.77

T/O Rate:1.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8809

EPS(LYR):-3.6445

ROE:-87.24%

ROA:-44.51%

PB:3.15

PE(LYR):-2.31

Loading ...

Overview Company News Filings

Kyverna Therapeutics - Extends $15 Mln Term a Loan Availability Through Dec 31, 2026 - SEC Filing

THOMSON REUTERS

Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer

Kyverna appoints Ritesh Srivastava as chief legal and compliance officer

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

THOMSON REUTERS

Health Rounds: CAR-T therapy brings hope to kidney patients with few transplant options

Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval

Kyverna Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Kyverna Therapeutics presents updated COMPARE trial data at EULAR

Kyverna says miv-cel CAR-T drives ACR70 response in Phase 1 trial in refractory ACPA-positive rheumatoid arthritis

Kyverna Therapeutics Highlights Updated Miv-Cel Data at Eular Demonstrating Substantial Reduction in Disease Activity in Acpa-Positive, Treatment Refractory Rheumatoid Arthritis

THOMSON REUTERS

Kyverna Therapeutics - Miv-Cel Demonstrates Well-Tolerated Safety Profile in Over 100 Patients

THOMSON REUTERS

Kyverna Therapeutics - Majority of Patients Meet Acr70 Response by Week 36 in Miv-Cel Phase 1 Trial

THOMSON REUTERS

Kyverna Therapeutics Stockholders Approve Directors and Auditor

Kyverna Therapeutics shareholders elect two directors at annual meeting

H.C. Wainwright Reaffirms Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)

Kyverna names CFO Gregory S. Martini in initial beneficial ownership filing

Kyverna Therapeutics Names Gregory Martini as New CFO

Kyverna names Greg Martini CFO, succeeding Marc Grasso

Kyverna Therapeutics Inc - Greg Martini Succeeds Marc Grasso as CFO

THOMSON REUTERS

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/KYTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":8.42,"timestamp":1787342400000,"preClose":8.13,"halted":0,"volume":663612,"hourTrading":{"tag":"盘后","latestPrice":8.452,"preClose":8.42,"latestTime":"19:30 EDT","volume":9637,"amount":81149.3365,"timestamp":1787355006604,"change":0.032,"changeRate":0.0038,"amplitude":0.0038},"delay":0,"changeRate":0.03567035670356693,"floatShares":39715000,"shares":61843444,"eps":-2.880877,"marketStatus":"Market Closed","change":0.29,"latestTime":"08-21 16:00:00 EDT","open":8.24,"high":8.58,"low":8.19,"amount":5556268.322597999,"amplitude":0.04797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.880877,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.13,"preHourTrading":{"tag":"盘前","latestPrice":8.24,"preClose":8.13,"latestTime":"09:22 EDT","volume":457,"amount":3796.3766899999996,"timestamp":1787318544349,"change":0.11,"changeRate":0.01353,"amplitude":0.121771},"postHourTrading":{"tag":"盘后","latestPrice":8.452,"preClose":8.42,"latestTime":"19:30 EDT","volume":9637,"amount":81149.3365,"timestamp":1787355006604,"change":0.032,"changeRate":0.0038,"amplitude":0.0038},"volumeRatio":0.7667172178993392,"impliedVol":1.1525,"impliedVolPercentile":0.4183},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":39715000,"roa":"-44.51%","roe":"-87.24%","lyrEps":-3.644532,"volumeRatio":0.7667172178993392,"shares":61843444,"dividePrice":0,"high":8.58,"amplitude":0.04797,"preClose":8.13,"low":8.19,"week52Low":3.5,"pbRate":"3.15","psRate":"1846.53","week52High":13.67,"institutionHeld":0,"latestPrice":8.42,"eps":-2.880877,"divideRate":0,"volume":663612,"delay":0,"ttmEps":-2.880877,"open":8.24,"prevYearClose":9.4,"prevWeekClose":8.17,"prevMonthClose":7.3,"prevQuarterClose":8.91,"fiveDayClose":8.17,"twentyDayClose":7.41,"sixtyDayClose":8.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"KYTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.63},{"market":"US","date":"2026-05-12","symbol":"KYTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-03-26","symbol":"KYTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.8,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.8},{"market":"US","date":"2025-11-12","symbol":"KYTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.97,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.85},{"market":"US","date":"2025-08-12","symbol":"KYTX","fiscalQuarterEnding":"2025/06","expectedEps":1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.97}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1755748800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2026-08-21","current":-2.922721,"percent":0.334385,"low":-26.836094,"twenty":-4.227182,"median":-2.842423,"eighty":-1.108015,"high":-0.615209,"avg":-4.328161,"sd":5.693054,"marketCap":502787199},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-27","current":-1.031292,"twenty":-8.738225,"median":-2.966787,"eighty":-0.98785,"marketCap":149969489},{"date":"2025-07-03","current":-0.835139,"twenty":-8.660987,"median":-2.95542,"eighty":-0.975365,"marketCap":121445033},{"date":"2025-07-11","current":-1.061012,"twenty":-8.20664,"median":-2.912794,"eighty":-0.974824,"marketCap":154291376},{"date":"2025-07-18","current":-1.209614,"twenty":-8.200961,"median":-2.836066,"eighty":-0.975365,"marketCap":175900813},{"date":"2025-07-25","current":-1.260138,"twenty":-8.178243,"median":-2.779231,"eighty":-0.975365,"marketCap":183248021},{"date":"2025-08-01","current":-1.061012,"twenty":-7.803407,"median":-2.688295,"eighty":-0.975365,"marketCap":154291376},{"date":"2025-08-08","current":-0.98374,"twenty":-7.78069,"median":-2.625776,"eighty":-0.98374,"marketCap":143054469},{"date":"2025-08-15","current":-0.964666,"twenty":-7.68982,"median":-2.585992,"eighty":-0.974824,"marketCap":153089661},{"date":"2025-08-22","current":-0.975567,"twenty":-7.678462,"median":-2.530603,"eighty":-0.962936,"marketCap":154819487},{"date":"2025-08-29","current":-1.008267,"twenty":-7.570554,"median":-2.118493,"eighty":-0.964666,"marketCap":160008967},{"date":"2025-09-05","current":-0.989192,"twenty":-7.52512,"median":-1.993646,"eighty":-0.964666,"marketCap":156981771},{"date":"2025-09-12","current":-1.130894,"twenty":-7.468327,"median":-1.952681,"eighty":-0.972792,"marketCap":179469518},{"date":"2025-09-19","current":-1.365248,"twenty":-7.429707,"median":-1.872701,"eighty":-0.975257,"marketCap":216660791},{"date":"2025-09-26","current":-1.730404,"twenty":-7.422892,"median":-1.802474,"eighty":-0.975365,"marketCap":274609985},{"date":"2025-10-03","current":-1.656828,"twenty":-7.377457,"median":-1.775165,"eighty":-0.975365,"marketCap":262933655},{"date":"2025-10-10","current":-1.923883,"twenty":-7.30249,"median":-1.765048,"eighty":-0.975527,"marketCap":305314409},{"date":"2025-10-17","current":-1.910257,"twenty":-7.150283,"median":-1.79077,"eighty":-0.977747,"marketCap":303152125},{"date":"2025-10-24","current":-1.74403,"twenty":-7.070773,"median":-1.806706,"eighty":-0.98265,"marketCap":276772268},{"date":"2025-10-31","current":-1.839406,"twenty":-7.009436,"median":-1.817606,"eighty":-0.98374,"marketCap":291908252},{"date":"2025-11-07","current":-1.932058,"twenty":-6.429007,"median":-1.834596,"eighty":-0.986404,"marketCap":306611779},{"date":"2025-11-14","current":-1.76583,"twenty":-6.028046,"median":-1.829785,"eighty":-0.98707,"marketCap":280231922},{"date":"2025-11-21","current":-2.023973,"twenty":-5.954216,"median":-1.856881,"eighty":-0.988768,"marketCap":325843504},{"date":"2025-11-28","current":-2.086542,"twenty":-5.791787,"median":-1.873766,"eighty":-0.989487,"marketCap":335916623},{"date":"2025-12-05","current":-2.132789,"twenty":-5.650939,"median":-1.874832,"eighty":-0.990456,"marketCap":343361972},{"date":"2025-12-12","current":-2.27425,"twenty":-5.604368,"median":-1.895008,"eighty":-0.995653,"marketCap":366135981},{"date":"2025-12-19","current":-1.904276,"twenty":-5.571428,"median":-1.899357,"eighty":-1.000453,"marketCap":306573190},{"date":"2025-12-26","current":-2.445634,"twenty":-5.541896,"median":-1.907532,"eighty":-1.00316,"marketCap":393727568},{"date":"2026-01-02","current":-3.335677,"twenty":-5.503276,"median":-1.923883,"eighty":-1.005937,"marketCap":537017328},{"date":"2026-01-09","current":-2.998561,"twenty":-5.448754,"median":-1.93164,"eighty":-1.007666,"marketCap":482744300},{"date":"2026-01-16","current":-3.094373,"twenty":-5.404456,"median":-1.947802,"eighty":-1.008709,"marketCap":498169266},{"date":"2026-01-23","current":-3.729571,"twenty":-5.372651,"median":-1.953858,"eighty":-1.010478,"marketCap":600431076},{"date":"2026-01-30","current":-2.913395,"twenty":-5.344255,"median":-1.965361,"eighty":-1.010992,"marketCap":469033219},{"date":"2026-02-06","current":-2.579827,"twenty":-5.065967,"median":-1.978384,"eighty":-1.01346,"marketCap":415331486},{"date":"2026-02-13","current":-2.611764,"twenty":-5.054609,"median":-2.003915,"eighty":-1.013717,"marketCap":420473142},{"date":"2026-02-20","current":-2.87436,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"marketCap":462748974},{"date":"2026-02-27","current":-2.881457,"twenty":-4.928528,"median":-2.043785,"eighty":-1.01438,"marketCap":463891564},{"date":"2026-03-06","current":-2.977269,"twenty":-4.827435,"median":-2.086542,"eighty":-1.020777,"marketCap":479316530},{"date":"2026-03-13","current":-3.112116,"twenty":-4.780255,"median":-2.118493,"eighty":-1.024754,"marketCap":501025741},{"date":"2026-03-20","current":-3.030498,"twenty":-4.769593,"median":-2.129165,"eighty":-1.025937,"marketCap":487885955},{"date":"2026-03-27","current":-3.012142,"twenty":-4.692966,"median":-2.151832,"eighty":-1.027873,"marketCap":484930840},{"date":"2026-04-02","current":-3.286851,"twenty":-4.628408,"median":-2.225282,"eighty":-1.029368,"marketCap":530192007},{"date":"2026-04-10","current":-3.590425,"twenty":-4.584311,"median":-2.250455,"eighty":-1.030802,"marketCap":579160710},{"date":"2026-04-17","current":-3.571686,"twenty":-4.573206,"median":-2.388506,"eighty":-1.03519,"marketCap":576137951},{"date":"2026-04-24","current":-3.358479,"twenty":-4.567056,"median":-2.487395,"eighty":-1.037789,"marketCap":541746122},{"date":"2026-05-01","current":-3.302191,"twenty":-4.561844,"median":-2.543569,"eighty":-1.038061,"marketCap":532666578},{"date":"2026-05-08","current":-3.489816,"twenty":-4.559102,"median":-2.569768,"eighty":-1.044783,"marketCap":562931724},{"date":"2026-05-15","current":-4.15662,"twenty":-4.534296,"median":-2.581654,"eighty":-1.052413,"marketCap":650095346},{"date":"2026-05-22","current":-3.444499,"twenty":-4.49595,"median":-2.613087,"eighty":-1.058444,"marketCap":538719607},{"date":"2026-05-29","current":-3.347743,"twenty":-4.480996,"median":-2.625776,"eighty":-1.061012,"marketCap":523587034},{"date":"2026-06-05","current":-3.076828,"twenty":-4.471909,"median":-2.688295,"eighty":-1.061714,"marketCap":481215829},{"date":"2026-06-12","current":-3.045866,"twenty":-4.449191,"median":-2.698705,"eighty":-1.063858,"marketCap":476373405},{"date":"2026-06-18","current":-3.11166,"twenty":-4.431665,"median":-2.713919,"eighty":-1.066038,"marketCap":486663555},{"date":"2026-06-26","current":-3.187473,"twenty":-4.412024,"median":-2.725319,"eighty":-1.06856,"marketCap":498520738},{"date":"2026-07-02","current":-3.280765,"twenty":-4.395806,"median":-2.779231,"eighty":-1.069929,"marketCap":513111589},{"date":"2026-07-10","current":-3.813306,"twenty":-4.390126,"median":-2.789213,"eighty":-1.073668,"marketCap":596401029},{"date":"2026-07-17","current":-2.892048,"twenty":-4.36173,"median":-2.806937,"eighty":-1.084606,"marketCap":452316377},{"date":"2026-07-24","current":-2.833741,"twenty":-4.344692,"median":-2.815944,"eighty":-1.092409,"marketCap":443197095},{"date":"2026-07-31","current":-2.911484,"twenty":-4.315412,"median":-2.817583,"eighty":-1.094857,"marketCap":455356137},{"date":"2026-08-07","current":-3.01255,"twenty":-4.26922,"median":-2.824699,"eighty":-1.099263,"marketCap":471162893},{"date":"2026-08-14","current":-3.273726,"twenty":-4.239266,"median":-2.836847,"eighty":-1.106454,"marketCap":499695027},{"date":"2026-08-21","current":-3.293984,"twenty":-4.227182,"median":-2.842423,"eighty":-1.108015,"marketCap":502787199}],"updateTime":1787522804568},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650313923","title":"Kyverna Therapeutics - Extends $15 Mln Term a Loan Availability Through Dec 31, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2650313923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650313923?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:06","pubTimestamp":1783591606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43A184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645223180","title":"Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645223180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645223180?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:11","pubTimestamp":1782130274,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) announced the appointment of Ritesh Srivastava as chief legal and compliance officer, effective June 22. Srivastava bri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-appoints-ritesh-srivastava-chief-legal-compliance-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-appoints-ritesh-srivastava-chief-legal-compliance-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902466","title":"Kyverna appoints Ritesh Srivastava as chief legal and compliance officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902466","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645902466?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:01","pubTimestamp":1782129703,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics appointed Ritesh Srivastava as chief legal and compliance officer, effective June 22, 2026.Move supports its transition toward commercialization as it advances miv-cel toward a potential first approval in stiff person syndrome.Srivastava most recently served as general counsel at BPGbio, advising on R&D, commercialization planning, and operations.He previously held senior compliance roles at Spectrum Pharmaceuticals and Avanir Pharmaceuticals, following earlier work as a federal prosecutor.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3rBHb9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","BK4139","SG9999014005.SGD","KYTX","NDAQ","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024559","title":"Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024559","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024559?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUABJ5S5G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641642781","title":"Health Rounds: CAR-T therapy brings hope to kidney patients with few transplant options","url":"https://stock-news.laohu8.com/highlight/detail?id=2641642781","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641642781?lang=en_us&edition=fundamental","pubTime":"2026-06-05 03:53","pubTimestamp":1780602793,"startTime":"0","endTime":"0","summary":"Health Rounds: CAR-T therapy brings hope to kidney patients with few transplant optionsHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidJune 4  - Hello Health Rounds readers!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nL1N42C0TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640864461","title":"Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2640864461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640864461?lang=en_us&edition=fundamental","pubTime":"2026-06-04 02:16","pubTimestamp":1780510572,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin has maintained their bullish stance on KYTX stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sami-corwin-initiates-buy-on-kyverna-kytx-on-differentiated-miv-cel-efficacy-and-advancing-bla-for-first-autoimmune-car-t-approval-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sami-corwin-initiates-buy-on-kyverna-kytx-on-differentiated-miv-cel-efficacy-and-advancing-bla-for-first-autoimmune-car-t-approval-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4022","CAR","BK4139","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640185385","title":"Kyverna Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2640185385","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640185385?lang=en_us&edition=fundamental","pubTime":"2026-06-04 00:23","pubTimestamp":1780503780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 12:23 ET (16:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890266","title":"Kyverna Therapeutics presents updated COMPARE trial data at EULAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640890266?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:00","pubTimestamp":1780491642,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) announced the presentation of updated data from the Phase 1 portion of COMPARE, a Phase 1/2 investigator-initiated tria...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-presents-updated-compare-trial-data-at-eular-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-presents-updated-compare-trial-data-at-eular-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640649901","title":"Kyverna says miv-cel CAR-T drives ACR70 response in Phase 1 trial in refractory ACPA-positive rheumatoid arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640649901","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640649901?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488045,"startTime":"0","endTime":"0","summary":"Kyverna highlighted updated Phase 1 COMPARE trial results for miv-cel in ACPA-positive, treatment-refractory rheumatoid arthritis, presented at EULAR 2026.Patients showed broad clinical improvement following a single infusion, supporting potential for meaningful disease control in a hard-to-treat population.Findings also pointed to durable suppression of disease-related immune activity while preserving protective vaccine immunity, consistent with an immune “reset” effect.Safety remained consistent with prior experience, with no severe cytokine release syndrome or neurotoxicity reported in the Phase 1 cohort.The randomized Phase 2 portion comparing miv-cel with rituximab has started and is fully enrolled, setting up a key read-through for differentiation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL9f4hY4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","KYTX","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901561","title":"Kyverna Therapeutics Highlights Updated Miv-Cel Data at Eular Demonstrating Substantial Reduction in Disease Activity in Acpa-Positive, Treatment Refractory Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901561?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA2LB051:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901169","title":"Kyverna Therapeutics - Miv-Cel Demonstrates Well-Tolerated Safety Profile in Over 100 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901169?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA2LB051:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640490116","title":"Kyverna Therapeutics - Majority of Patients Meet Acr70 Response by Week 36 in Miv-Cel Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640490116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640490116?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA2LB051:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640290509","title":"Kyverna Therapeutics Stockholders Approve Directors and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2640290509","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640290509?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:28","pubTimestamp":1780439335,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc. ( ($KYTX) ) has shared an update. On May 27, 2026, Kyverna Therapeutics, Inc. held its 2026 Annual Meeting of Stockholde...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640925119","title":"Kyverna Therapeutics shareholders elect two directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640925119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640925119?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:33","pubTimestamp":1780432382,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics held its annual shareholder meeting on May 27, 2026.Shareholders backed the selection of Ian Clark, Christi Shaw as Class II directors, with terms running to the 2029 annual meeting.Shareholders ratified BDO USA, P.C. as independent registered public accounting firm for the year ending Dec. 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2rPjcM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638354456","title":"H.C. Wainwright Reaffirms Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638354456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638354456?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:56","pubTimestamp":1779818164,"startTime":"0","endTime":"0","summary":"In a report released today, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Kyverna Therapeutics, Inc., with a price target of $25....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-kyverna-therapeutics-inc-kytx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-kyverna-therapeutics-inc-kytx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637873619","title":"Kyverna names CFO Gregory S. Martini in initial beneficial ownership filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2637873619","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637873619?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:30","pubTimestamp":1779309047,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics filed an initial beneficial ownership statement for Chief Financial Officer Gregory S. Martini.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDLbSFLpN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636668075","title":"Kyverna Therapeutics Names Gregory Martini as New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2636668075","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636668075?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:40","pubTimestamp":1779108008,"startTime":"0","endTime":"0","summary":"The latest update is out from Kyverna Therapeutics, Inc. ( ($KYTX) ). Kyverna Therapeutics appointed Gregory (Greg) Martini as chief financial offi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-names-gregory-martini-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-names-gregory-martini-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073821","title":"Kyverna names Greg Martini CFO, succeeding Marc Grasso","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073821","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073821?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:03","pubTimestamp":1779105785,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics appointed Greg Martini as chief financial officer, effective May 18, 2026.Martini most recently served as senior vice president and CFO at Ironwood Pharmaceuticals, leading capital allocation, treasury, investor relations, and cost-saving initiatives tied to its commercial expansion.He previously held strategic finance and investor relations roles at Ironwood, earlier finance and corporate development posts at Thermo Fisher Scientific, and roles at Ernst & Young and Raytheon Technologies.Martini succeeds Marc Grasso, who will remain as a consultant during the transition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9WTnw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854103824.USD","LU1923622614.USD","LU1023059063.AUD","LU0070302665.USD","BK4566","IE00BQXX3C00.GBP","LU1929549753.HKD","IE00BQXX3F31.USD","LU2125909759.SGD","LU0234572021.USD","LU0208291251.USD","IRWD","LU2468319806.SGD","LU0320765646.SGD","LU2764263039.SGD","LU2433249047.HKD","BK4534","LU2720916845.USD","IE00B3S45H60.SGD","LU1712237335.SGD","LU1623119135.USD","LU1670628061.USD","IE00BFTCPJ56.SGD","LU1720051017.SGD","LU1923622291.USD","LU2125910179.SGD","TMO","RTX","BK4585","LU0882574055.USD","IE00B19Z9505.USD","IE00B19Z8X17.USD","LU2211815571.USD","LU2764263203.CNY","LU0823416689.USD","RTXG","LU0316494557.USD","LU2112291526.USD","KYTX","LU2543165471.USD","LU2063271972.USD","IE00BQXX3D17.EUR","BK4187","BK4139","LU0096362180.USD","LU2125909916.SGD","LU2125910336.SGD","BK4581","LU2211814178.USD","LU1989771016.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636787300","title":"Kyverna Therapeutics Inc - Greg Martini Succeeds Marc Grasso as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2636787300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636787300?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA14SGBC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078781","title":"Kyverna Therapeutics Names Greg Martini as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078781","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078781?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA14SGBC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":96,"code":"91000000","status":"200"}]}}